




RealRate

PHARMACEUTICAL 2018

Agios Pharmaceuticals INC
Rank 185 of 332



The relative strengths and weaknesses of Agios Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Agios Pharmaceuticals INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 31% points. The greatest weakness of Agios Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is 244%, being 7.6% points below the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	445,261
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	94,941
Liabilities, Non-Current	0
Other Assets	144,705
Other Compr. Net Income	-1,076
Other Expenses	0
Other Liabilities	143,953
Other Net Income	6,124
Other Revenues	43,011
Property and Equipment	24,431
Research and Development	292,681
Selling, General and Administrative Expense	71,124

Output Variable	Value in 1000 USD
Assets	614,397
Liabilities	238,894
Expenses	363,805
Revenues	43,011
Stockholders Equity	375,503
Net Income	-314,670
Comprehensive Net Income	-315,208
BaseVar	633,654
ECR before Limited Liability	118%
Economic Capital Ratio	244%